Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18403342 | 0.87 | SLC34A1 (0.44) | KDM4EMAPTTHRBGPR119KMT2A | |
| SCHEMBL4235039 | 0.86 | MAPT (0.51) | KDM4EMAPTTHRBGPR119HTT | |
| SCHEMBL15890099 | 0.86 | THRB (0.51) | KDM4EMAPTTHRBGPR119HTT | |
| SCHEMBL17796475 | 0.86 | THRB (0.51) | KDM4EMAPTTHRBGPR119HTT | |
| SCHEMBL19937645 | 0.84 | MAPT (0.49) | KDM4EMAPTTHRBGPR119HTT | |
| SCHEMBL5453963 | 0.84 | KDM4E (0.49) | KDM4EMAPTTHRBGPR119HTT | |
| SCHEMBL18403235 | 0.83 | KDM4E (0.48) | KDM4EMAPTTHRBGPR119HTT | |
| SCHEMBL18685612 | 0.81 | MAP3K12 (0.53) | KDM4E | |
| SCHEMBL16827791 | 0.79 | MEN1 (0.60) | MAPTTHRBHPGDKMT2A | |
| SCHEMBL15824692 | 0.79 | HTT (0.51) | KDM4EMAPTTHRBGPR119HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2945938-B1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-03-07 | — | — | EP | disclosed |
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | PDXK, NLK, PDK3 | KDM4E 732/4885MAPT 494/4885THRB 3281/4885 |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | PDXK, NLK, PDK3 | KDM4E 732/4885MAPT 494/4885THRB 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.